We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
6 Reasons Why Insperity (NSP) Should Be in Your Portfolio
Read MoreHide Full Article
Insperity, Inc. (NSP - Free Report) has performed extremely well so far this year and has the potential to sustain the momentum in the near term. Therefore, if you haven’t taken advantage of the share price appreciation yet, it’s time you add this staffing stock to your portfolio.
Why an Attractive Pick?
Share Price Appreciation: A glimpse of the company’s price trend reveals that the stock has had an impressive run on the bourse year to date. Insperity’s shares have surged 27.9%, significantly outperforming the 10.4% rally of the industry it belongs to.
Solid Rank & VGM Score: Insperity currently has a Zacks Rank #2 (Buy) and a VGM Score of B. Our research shows that stocks with a VGM Score of A or B when combined with a Zacks Rank #1 (Strong Buy) or #2 offer the best investment opportunities for investors. Thus, the company appears to be a compelling investment proposition at the moment. You can see the complete list of today’s Zacks #1 Rank stocks here.
Northward Estimate Revisions: Four estimates for 2019 moved north over the past 60 days versus no southward revision, reflecting analysts’ confidence in the company. Over this period, the Zacks Consensus Estimate for 2019 increased 2.2%.
Positive Earnings Surprise History: Insperity has an impressive earnings surprise history. The company outpaced the Zacks Consensus Estimate in all of the trailing four quarters, delivering a positive average surprise of 10.5%.
Strong Growth Prospects: The Zacks Consensus Estimate for 2019 earnings is currently pegged at $4.69, reflecting year-over-year growth of 25.1%. Moreover, earnings are expected to register 17.4% growth in 2020. The stock has a long-term expected EPS growth rate of 18%.
Growth Drivers: Insperity has a business model that supports consistent predictable growth, management of price and cost, and operating leverage. The company has a vast market opportunity.
Insperity’s sales are in great shape, driven by strong worksite employee growth and high client retention. The company is also in the process of increasing the number of its business process advisors (BPAs) to drive sales.
Insperity’s marketing programs - digital, loyalty programs and channel partners continue to be effective and complement its sales efforts. It has added an authority marketing program and new targeted advertising to its marketing mix to support its growing sales team.
Other Stocks to Consider
Some other top-ranked stocks in the broader Zacks Business Services sector are Navigant Consulting (NCI) , FLEETCOR Technologies and NV5 Global (NVEE - Free Report) . While Navigant Consulting sports a Zacks Rank #1, FLEETCOR and NV5 Global carry a Zacks Rank #2.
Long-term expected EPS (three to five years) growth rate for Navigant Consulting, FLEETCOR and NV5 Global is 13.5%, 15.4% and 20%, respectively.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
6 Reasons Why Insperity (NSP) Should Be in Your Portfolio
Insperity, Inc. (NSP - Free Report) has performed extremely well so far this year and has the potential to sustain the momentum in the near term. Therefore, if you haven’t taken advantage of the share price appreciation yet, it’s time you add this staffing stock to your portfolio.
Why an Attractive Pick?
Share Price Appreciation: A glimpse of the company’s price trend reveals that the stock has had an impressive run on the bourse year to date. Insperity’s shares have surged 27.9%, significantly outperforming the 10.4% rally of the industry it belongs to.
Solid Rank & VGM Score: Insperity currently has a Zacks Rank #2 (Buy) and a VGM Score of B. Our research shows that stocks with a VGM Score of A or B when combined with a Zacks Rank #1 (Strong Buy) or #2 offer the best investment opportunities for investors. Thus, the company appears to be a compelling investment proposition at the moment. You can see the complete list of today’s Zacks #1 Rank stocks here.
Northward Estimate Revisions: Four estimates for 2019 moved north over the past 60 days versus no southward revision, reflecting analysts’ confidence in the company. Over this period, the Zacks Consensus Estimate for 2019 increased 2.2%.
Positive Earnings Surprise History: Insperity has an impressive earnings surprise history. The company outpaced the Zacks Consensus Estimate in all of the trailing four quarters, delivering a positive average surprise of 10.5%.
Strong Growth Prospects: The Zacks Consensus Estimate for 2019 earnings is currently pegged at $4.69, reflecting year-over-year growth of 25.1%. Moreover, earnings are expected to register 17.4% growth in 2020. The stock has a long-term expected EPS growth rate of 18%.
Growth Drivers: Insperity has a business model that supports consistent predictable growth, management of price and cost, and operating leverage. The company has a vast market opportunity.
Insperity’s sales are in great shape, driven by strong worksite employee growth and high client retention. The company is also in the process of increasing the number of its business process advisors (BPAs) to drive sales.
Insperity, Inc. Revenue (TTM)
Insperity, Inc. revenue-ttm | Insperity, Inc. Quote
Insperity’s marketing programs - digital, loyalty programs and channel partners continue to be effective and complement its sales efforts. It has added an authority marketing program and new targeted advertising to its marketing mix to support its growing sales team.
Other Stocks to Consider
Some other top-ranked stocks in the broader Zacks Business Services sector are Navigant Consulting (NCI) , FLEETCOR Technologies and NV5 Global (NVEE - Free Report) . While Navigant Consulting sports a Zacks Rank #1, FLEETCOR and NV5 Global carry a Zacks Rank #2.
Long-term expected EPS (three to five years) growth rate for Navigant Consulting, FLEETCOR and NV5 Global is 13.5%, 15.4% and 20%, respectively.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>